Should I buy or sell Merck & Co., Inc. stock right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRK shares. View MRK analyst ratings or view top-rated stocks .

What is Merck & Co., Inc.'s stock price target for 2024?

21 Wall Street research analysts have issued 1 year price objectives for Merck & Co., Inc.'s stock. Their MRK share price targets range from $115.00 to $135.00. On average, they expect the company's share price to reach $125.14 in the next twelve months. This suggests a possible upside of 22.1% from the stock's current price. View analysts price targets for MRK or view top-rated stocks among Wall Street analysts .

How have MRK shares performed in 2023?

Merck & Co., Inc.'s stock was trading at $110.95 at the beginning of 2023. Since then, MRK shares have decreased by 7.6% and is now trading at $102.48. View the best growth stocks for 2023 here .

When is Merck & Co., Inc.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024. View our MRK earnings forecast .

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) announced its earnings results on Thursday, October, 26th. The company reported $2.13 EPS for the quarter, beating the consensus estimate of $1.94 by $0.19. The firm earned $16 billion during the quarter, compared to analysts' expectations of $15.30 billion. Merck & Co., Inc. had a net margin of 7.77% and a trailing twelve-month return on equity of 18.26%. Merck & Co., Inc.'s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.85 earnings per share. Read the conference call transcript .

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, November 28th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.77 per share on Monday, January 8th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date of this dividend is Thursday, December 14th. This is an increase from the stock's previous quarterly dividend of $0.73. Read our dividend analysis for MRK .

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. (NYSE:MRK) pays an annual dividend of $2.92 per share and currently has a dividend yield of 2.91%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 162.22%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MRK will have a dividend payout ratio of 34.35% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for MRK .

What ETFs hold Merck & Co., Inc.'s stock?

ETFs with the largest weight of Merck & Co., Inc. (NYSE:MRK) stock in their portfolio include First Trust Nasdaq Pharmaceuticals ETF (FTXH) , Invesco S&P 500 Momentum ETF (SPMO) , Invesco Pharmaceuticals ETF (PJP) , Health Care Select Sector SPDR Fund (XLV) , iShares U.S. Healthcare ETF (IYH) , Vanguard Health Care ETF (VHT) , Optimize AI Smart Sentiment Event-Driven ETF (OAIE) and VanEck Pharmaceutical ETF (PPH) .

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY23 earnings guidance on Thursday, October, 26th. The company provided earnings per share guidance of $1.33-$1.38 for the period, compared to the consensus estimate of $3.03. The company issued revenue guidance of $59.7-$60.2 billion, compared to the consensus revenue estimate of $59.32 billion.

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. Chief Executive Officer Kenneth C. Frazier on Glassdoor.com . Kenneth C. Frazier has an approval rating of 94% among the company's employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE) , Johnson & Johnson (JNJ) , AT&T (T) , Intel (INTC) , Cisco Systems (CSCO) , Walt Disney (DIS) , Verizon Communications (VZ) , JPMorgan Chase & Co. (JPM) , AbbVie (ABBV) and Home Depot (HD) .

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (1.52%), FMR LLC (1.51%), Charles Schwab Investment Management Inc. (1.26%), Northern Trust Corp (1.18%), Bank of New York Mellon Corp (0.98%) and Legal & General Group Plc (0.79%). Insiders that own company stock include Caroline Litchfield , Frank Clyburn , Johannes Jacobus Oosthuizen , Joseph Romanelli , Kenneth C Frazier , Richard R Deluca , Rita A Karachun , Robert M Davis , Sanat Chattopadhyay and Steven Mizell . View institutional ownership trends .

How do I buy shares of Merck & Co., Inc.?

Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Top-Rated Dividend StocksTop-Rated Dividend

Merck & Co., Inc. Stock Price, News & Analysis (NYSE:MRK)

$102.48

+1.35 (+1.33%)

(As of 11/30/2023 ET)

Compare

Today's Range: $100.28
▼
$102.69
50-Day Range: $100.17
▼
$106.33
52-Week Range: $96.36
▼
$119.65

Volume: 27.25 million shs
Average Volume: 7.55 million shs
Market Capitalization: $259.69 billion

P/E Ratio: 56.93
Dividend Yield: 2.85%
Price Target: $125.14

Merck & Co., Inc. MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.76 Rating Score
Upside/Downside: 22.1% Upside
$125.14 Price Target
Short Interest: Healthy
0.71% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.40
Upright™ Environmental Score
News Sentiment: 1.05
Based on 16 Articles This Week
Insider Trading: Selling Shares
$4.82 M Sold Last Quarter
Proj. Earnings Growth: 520.44%
From $1.37 to $8.50 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.20 out of 5 stars

Medical Sector

14th out of 949 stocks

Pharmaceutical Preparations Industry

5th out of 435 stocks

3.4

Analyst's Opinion

Consensus Rating
Merck & Co., Inc. has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 16 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $125.14, Merck & Co., Inc. has a forecasted upside of 22.1% from its current price of $102.48.
Amount of Analyst Coverage
Merck & Co., Inc. has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.71% of the outstanding shares of Merck & Co., Inc. have been sold short.
Short Interest Ratio / Days to Cover
Merck & Co., Inc. has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Merck & Co., Inc. has recently increased by 9.81%, indicating that investor sentiment is decreasing significantly.

3.3

Dividend Strength

Dividend Yield
Merck & Co., Inc. pays a meaningful dividend of 2.91%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Merck & Co., Inc. has been increasing its dividend for 12 years.
Dividend Coverage
The dividend payout ratio of Merck & Co., Inc. is 162.22%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 34.35% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Merck & Co., Inc. has received a 55.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Papillomavirus vaccines", "Pembrolizumab", and "Antiviral medication (J05)" products. See details.
Environmental Sustainability
The Environmental Impact score for Merck & Co., Inc. is -2.40.

2.8

News and Social Media Coverage

News Sentiment
Merck & Co., Inc. has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 16 news articles for Merck & Co., Inc. this week, compared to 12 articles on an average week.
Search Interest
Only 71 people have searched for MRK on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.
MarketBeat Follows
Only 25 people have added Merck & Co., Inc. to their MarketBeat watchlist in the last 30 days. This is a decrease of -46% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merck & Co., Inc. insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,815,782.00 in company stock.
Percentage Held by Insiders
Only 0.20% of the stock of Merck & Co., Inc. is held by insiders.
Percentage Held by Institutions
74.59% of the stock of Merck & Co., Inc. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Merck & Co., Inc. are expected to grow by 520.44% in the coming year, from $1.37 to $8.50 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Merck & Co., Inc. is 56.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.98.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merck & Co., Inc. is 56.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 113.00.
Price to Earnings Growth Ratio
Merck & Co., Inc. has a PEG Ratio of 8.48. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Merck & Co., Inc. has a P/B Ratio of 6.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Merck & Co., Inc. Stock (NYSE:MRK)

Merck & Co., Inc. is a US-based multinational pharmaceutical and healthcare company. It was officially founded in 1891 as the US arm of Merck Group, headquartered in Germany. Merck Group was founded in 1668 when Friedrick Jacob Merck purchased a pharmacy in Darmstadt, Germany. The company transformed from a pharmacy into a drug manufacturer in 1827 with the commercialization of morphine and the perfection of the manufacturing process. The company will later gain recognition for isolating and commercializing the manufacture of cocaine as well.

Merck Group sent Theodore Weicker to New York as its representative in 1889 and he quickly began to set up operations. The original investment of $200,000 resulted in a facility in lower Manhattan and the addition of Merck family member George Merck to the project. They began operations in 1891 and were in business as the US branch of Merck Group until 1917 and the onset of World War I.

World War I brought about the Trading With The Enemy Act of 1917 and the nationalization of Merck Group’s US operations. Those operations were repurchased at a government auction only 2 years later with the help of Goldman Sachs and Lehman Brothers, but the split was done. The company retained rights to the Merck name in the US but remained independent. One of many noteworthy achievements in the post-War period is the discovery of streptomycin, which was revolutionary in treating tuberculosis.

In 1953 the company merged with Sharp& Dohme to form the then 2nd largest US drug manufacturer. The merger brought smallpox vaccines to the portfolio and opened a new avenue of research for the business. Since then, advancements in vaccine technology include treatments for mumps and chickenpox. Other notable advancements include the discovery of statins as a cholesterol inhibitor and work in veterinary medicine.

Today, Merck & Co operates through 2 segments and under 2 different names with a headquarters in Kenilworth, NJ. The company operates as Merck & Co in the US and as Merck Sharp & Dohme outside the US and Canada. The 2 segments are Pharmaceutical and Animal Health. Revenue topped $49 billion in 2022 and employed more than 68,000 people. The company has 8 research facilities near major university systems, including 7 in the US and 1 in the UK. As of 2022, the company had 82 pipeline products in Phase 2 trials, 30 in Phase 3 trials and 3 under review.

The Pharmaceutical segment researches discover and commercializes human health products in several areas of medicine. These include but are not limited to oncology, acute care, immunology, neuroscience, virology, cardiovascular, and diabetes. This segment has 6 blockbuster drugs as of late 2022, with each generating more than $1 billion in revenue. The leading treatments are Keytruda for treating cancer-related immune conditions, Gardisil which is a vaccine for HPV and Januvia for treating Type-II diabetes. The Animal Health segment discovers, develops, manufactures, and markets veterinary healthcare products and services. Both segments sell to healthcare facilities and distributors.

MRK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MRK Stock News Headlines

November 13, 2023 | marketbeat.com

3 S&P stocks with growth to weather a downturn (MRK)

S&P 500 components Broadcom, McCormick and Merck stocks are diverse stocks worth tracking for investors seeking strong earnings and dividend growth.

November 1, 2023 | marketbeat.com

Investor patience tested as pharmaceutical stocks take a tumble (MRK)

The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector

December 1, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 30, 2023 | finance.yahoo.com

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) for the First-Line Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

November 30, 2023 | americanbankingnews.com

Merck & Co., Inc.'s (MRK) Overweight Rating Reaffirmed at Cantor Fitzgerald

November 29, 2023 | finance.yahoo.com

12 Best Quality Stocks To Buy Now

November 29, 2023 | finance.yahoo.com

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

November 28, 2023 | finance.yahoo.com

Merck Announces First-Quarter 2024 Dividend

December 1, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 28, 2023 | finance.yahoo.com

Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older

November 25, 2023 | finance.yahoo.com

Merck (NYSE:MRK) shareholders have earned a 9.4% CAGR over the last five years

November 23, 2023 | seekingalpha.com

Merck Will Keep Your Retirement Income Healthy

November 22, 2023 | finance.yahoo.com

Merck (MRK) to Acquire Private Neuroscience Company for $610M

November 22, 2023 | finance.yahoo.com

20 Healthiest States in the US in 2023

November 22, 2023 | seekingalpha.com

Merck: Not The Time To Be Adding

November 22, 2023 | seekingalpha.com

Merck: Keytruda Patent Expiry Nears With Replacement Yet To Be Found

November 22, 2023 | americanbankingnews.com

Stock Traders Buy Large Volume of Merck & Co., Inc. Call Options (NYSE:MRK)

November 21, 2023 | finance.yahoo.com

UPDATE 1-Merck to acquire Caraway Therapeutics for up to $610 mln

November 21, 2023 | americanbankingnews.com

Merck & Co., Inc. (NYSE:MRK) Given Average Rating of "Moderate Buy" by Brokerages

November 20, 2023 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Fresenius Medical Care (FMS), Solid Biosciences (SLDB) and Merck & Company (MRK)

November 20, 2023 | finance.yahoo.com

Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference

November 17, 2023 | finance.yahoo.com

Merck (MRK) Gets FDA Nod for Keytruda Expansion in Gastric Cancer

November 16, 2023 | finance.yahoo.com

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

November 16, 2023 | seekingalpha.com

Merck & Co., Inc. (MRK) Jefferies London Healthcare Conference (Transcript)

November 16, 2023 | seekingalpha.com

Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference (Transcript)

November 14, 2023 | finance.yahoo.com

The S&P 500 Has Two Companies to Thank for the Slide in Earnings Estimates

November 14, 2023 | finance.yahoo.com

Earnings Estimates Are Falling. These Two Companies Are Shouldering the Blame.

See More Headlines

Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 10/6 Dividend: 9/14/2023
Dividend Payable: 10/06/2023
Last Earnings: 10/26/2023
Today: 11/30/2023
Ex-Dividend for 1/8 Dividend: 12/14/2023
Fiscal Year End: 12/31/2023
Dividend Payable: 1/08/2024
Next Earnings (Estimated): 2/01/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:MRK
CUSIP: 58933Y10
CIK: 310158
Web: www.merck.com
Phone: (908) 740-4000
Fax: 908-735-1253
Employees: 69,000
Year Founded: 1891

Price Target and Rating

Average Stock Price Target: $125.14
High Stock Price Target: $135.00
Low Stock Price Target: $115.00
Potential Upside/Downside: +23.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.76
Research Coverage: 21 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.80
Trailing P/E Ratio: 56.53
Forward P/E Ratio: 74.27
P/E Growth: 8.48
Net Income: $14.52 billion
Net Margins: 7.77%
Pretax Margin: 12.56%
Return on Equity: 18.26%
Return on Assets: 7.38%

Debt

Debt-to-Equity Ratio: 0.82
Current Ratio: 1.38
Quick Ratio: 1.12

Sales & Book Value

Annual Sales: $59.28 billion
Price / Sales: 4.35
Cash Flow: $9.17 per share
Price / Cash Flow: 11.09
Book Value: $16.30 per share
Price / Book: 6.24

Miscellaneous

Outstanding Shares: 2,534,020,000
Free Float: 2,528,955,000
Market Cap: $257.84 billion
Optionable: Optionable
Beta: 0.37

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Robert M. Davis J.D. (Age 56)
Chairman, President & CEO
Comp: $6.08M
Ms. Caroline Litchfield (Age 54)
Executive VP & CFO
Comp: $2.8M
Ms. Jennifer L. Zachary (Age 45)
Executive VP & General Counsel
Comp: $2.73M
Dr. Dean Y. Li M.D. (Age 61)
Ph.D., Executive VP & President of Merck Research Laboratories
Comp: $3.44M
Mr. Chirfi Guindo (Age 57)
Senior VP & Chief Marketing Officer for Merck Human Health
Comp: $1.54M
Mr. David Michael Williams (Age 54)
Executive VP and Chief Information & Digital Officer
Mr. Peter Dannenbaum
Vice President of Investor Relations
Lisa LeCointe-Cephas (Age 41)
Senior VP and Chief Ethics & Compliance Officer
Ms. Cristal N. Downing (Age 53)
Executive VP and Chief Communications & Public Affairs Officer
Mr. Steven C. Mizell (Age 63)
Executive VP & Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MRK Stock Analysis - Frequently Asked Questions

Should I buy or sell Merck & Co., Inc. stock right now?: 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRK shares.
View MRK analyst ratings or view top-rated stocks.
What is Merck & Co., Inc.'s stock price target for 2024?: 21 Wall Street research analysts have issued 1 year price objectives for Merck & Co., Inc.'s stock. Their MRK share price targets range from $115.00 to $135.00. On average, they expect the company's share price to reach $125.14 in the next twelve months. This suggests a possible upside of 22.1% from the stock's current price.
View analysts price targets for MRK or view top-rated stocks among Wall Street analysts.
How have MRK shares performed in 2023?: Merck & Co., Inc.'s stock was trading at $110.95 at the beginning of 2023. Since then, MRK shares have decreased by 7.6% and is now trading at $102.48.
View the best growth stocks for 2023 here.
When is Merck & Co., Inc.'s next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024.
View our MRK earnings forecast.
How were Merck & Co., Inc.'s earnings last quarter?: Merck & Co., Inc. (NYSE:MRK) announced its earnings results on Thursday, October, 26th. The company reported $2.13 EPS for the quarter, beating the consensus estimate of $1.94 by $0.19. The firm earned $16 billion during the quarter, compared to analysts' expectations of $15.30 billion. Merck & Co., Inc. had a net margin of 7.77% and a trailing twelve-month return on equity of 18.26%. Merck & Co., Inc.'s quarterly revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.85 earnings per share.
Read the conference call transcript.
How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?: Merck & Co., Inc. announced a quarterly dividend on Tuesday, November 28th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.77 per share on Monday, January 8th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date of this dividend is Thursday, December 14th. This is an increase from the stock's previous quarterly dividend of $0.73.
Read our dividend analysis for MRK.
Is Merck & Co., Inc. a good dividend stock?: Merck & Co., Inc. (NYSE:MRK) pays an annual dividend of $2.92 per share and currently has a dividend yield of 2.91%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 162.22%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, MRK will have a dividend payout ratio of 34.35% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MRK.

What ETFs hold Merck & Co., Inc.'s stock?: ETFs with the largest weight of Merck & Co., Inc. (NYSE:MRK) stock in their portfolio include First Trust Nasdaq Pharmaceuticals ETF (FTXH), Invesco S&P 500 Momentum ETF (SPMO), Invesco Pharmaceuticals ETF (PJP), Health Care Select Sector SPDR Fund (XLV), iShares U.S. Healthcare ETF (IYH), Vanguard Health Care ETF (VHT), Optimize AI Smart Sentiment Event-Driven ETF (OAIE) and VanEck Pharmaceutical ETF (PPH).
What guidance has Merck & Co., Inc. issued on next quarter's earnings?: Merck & Co., Inc. updated its FY23 earnings guidance on Thursday, October, 26th. The company provided earnings per share guidance of $1.33-$1.38 for the period, compared to the consensus estimate of $3.03. The company issued revenue guidance of $59.7-$60.2 billion, compared to the consensus revenue estimate of $59.32 billion.
What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?: 1,343 employees have rated Merck & Co., Inc. Chief Executive Officer Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among the company's employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Merck & Co., Inc. own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).
Who are Merck & Co., Inc.'s major shareholders?: Merck & Co., Inc.'s stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (1.52%), FMR LLC (1.51%), Charles Schwab Investment Management Inc. (1.26%), Northern Trust Corp (1.18%), Bank of New York Mellon Corp (0.98%) and Legal & General Group Plc (0.79%). Insiders that own company stock include Caroline Litchfield, Frank Clyburn, Johannes Jacobus Oosthuizen, Joseph Romanelli, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay and Steven Mizell.
View institutional ownership trends.
How do I buy shares of Merck & Co., Inc.?: Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:MRK) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial